Research ExplorerPublicationsFOXO1 overexpression and loss of pSerine256-FOXO1 expression...

FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas

Standard

FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas. / Grupp, Katharina; Uzunoglu, Faik Güntac; Melling, Nathaniel; Hofmann, Bianca; El Gammal, Alexander Tarek; Grotelüschen, Rainer; Heumann, Asmus; Bellon, Eugen; Reeh, Matthias; Wolters-Eisfeld, Gerrit; Ghabdan, Tarik; Nentwich, Michael; Bachmann, Kai; Bockhorn, Maximillian; Bogoevski, Dean; Izbicki, Jakob Robert; Kutup, Asad.

In: SCI REP-UK, Vol. 8, No. 1, 26.11.2018, p. 17370.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Grupp, K, Uzunoglu, FG, Melling, N, Hofmann, B, El Gammal, AT, Grotelüschen, R, Heumann, A, Bellon, E, Reeh, M, Wolters-Eisfeld, G, Ghabdan, T, Nentwich, M, Bachmann, K, Bockhorn, M, Bogoevski, D, Izbicki, JR & Kutup, A 2018, 'FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas', SCI REP-UK, vol. 8, no. 1, pp. 17370. https://doi.org/10.1038/s41598-018-35459-4

APA

Grupp, K., Uzunoglu, F. G., Melling, N., Hofmann, B., El Gammal, A. T., Grotelüschen, R., Heumann, A., Bellon, E., Reeh, M., Wolters-Eisfeld, G., Ghabdan, T., Nentwich, M., Bachmann, K., Bockhorn, M., Bogoevski, D., Izbicki, J. R., & Kutup, A. (2018). FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas. SCI REP-UK, 8(1), 17370. https://doi.org/10.1038/s41598-018-35459-4

Vancouver

Grupp K, Uzunoglu FG, Melling N, Hofmann B, El Gammal AT, Grotelüschen R et al. FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas. SCI REP-UK. 2018 Nov 26;8(1):17370. https://doi.org/10.1038/s41598-018-35459-4

Bibtex

@article{2a2da43e05924cdeb8a6588366fa9be5,
title = "FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas",
abstract = "The function of Forkhead box O 1 (FOXO1) and pSerine256-FOXO1 immunostaining in esophageal cancer is unclear. To clarify the prognostic role of nuclear FOXO1 and cytoplasmic pSerine256-FOXO1 immunostaining, a tissue microarray containing more than 600 esophageal cancers was analyzed. In non-neoplastic esophageal mucosae, FOXO1 expression was detectable in low and pSerine256-FOXO1 expression in high intensities. Increased FOXO1 and decreased pSerine256-FOXO1 expression were linked to advanced tumor stage and high UICC stage in esophageal adenocarcinomas (EACs) (tumor stage: p = 0.0209 and p < 0.0001; UICC stage: p = 0.0201 and p < 0.0001) and squamous cell carcinomas (ESCCs) (tumor stage: p = 0.0003 and p = 0.0016; UICC stage: p = 0.0026 and p = 0.0326). Additionally, overexpression of FOXO1 and loss of pSerine256-FOXO1 expression predicted shortened survival of patients with EACs (p = 0.0003 and p = 0.0133) but were unrelated to outcome in patients with ESCCs (p = 0.7785 and p = 0.8426). In summary, our study shows that overexpression of nuclear FOXO1 and loss of cytoplasmic pSerine256-FOXO1 expression are associated with poor prognosis in patients with EACs. Thus, evaluation of FOXO1 and pSerine256-FOXO1 protein expression - either alone or in combination with other markers - might be useful for prediction of clinical outcome in patients with EAC.",
keywords = "Journal Article",
author = "Katharina Grupp and Uzunoglu, {Faik G{\"u}ntac} and Nathaniel Melling and Bianca Hofmann and {El Gammal}, {Alexander Tarek} and Rainer Grotel{\"u}schen and Asmus Heumann and Eugen Bellon and Matthias Reeh and Gerrit Wolters-Eisfeld and Tarik Ghabdan and Michael Nentwich and Kai Bachmann and Maximillian Bockhorn and Dean Bogoevski and Izbicki, {Jakob Robert} and Asad Kutup",
year = "2018",
month = nov,
day = "26",
doi = "10.1038/s41598-018-35459-4",
language = "English",
volume = "8",
pages = "17370",
journal = "SCI REP-UK",
issn = "2045-2322",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas

AU - Grupp, Katharina

AU - Uzunoglu, Faik Güntac

AU - Melling, Nathaniel

AU - Hofmann, Bianca

AU - El Gammal, Alexander Tarek

AU - Grotelüschen, Rainer

AU - Heumann, Asmus

AU - Bellon, Eugen

AU - Reeh, Matthias

AU - Wolters-Eisfeld, Gerrit

AU - Ghabdan, Tarik

AU - Nentwich, Michael

AU - Bachmann, Kai

AU - Bockhorn, Maximillian

AU - Bogoevski, Dean

AU - Izbicki, Jakob Robert

AU - Kutup, Asad

PY - 2018/11/26

Y1 - 2018/11/26

N2 - The function of Forkhead box O 1 (FOXO1) and pSerine256-FOXO1 immunostaining in esophageal cancer is unclear. To clarify the prognostic role of nuclear FOXO1 and cytoplasmic pSerine256-FOXO1 immunostaining, a tissue microarray containing more than 600 esophageal cancers was analyzed. In non-neoplastic esophageal mucosae, FOXO1 expression was detectable in low and pSerine256-FOXO1 expression in high intensities. Increased FOXO1 and decreased pSerine256-FOXO1 expression were linked to advanced tumor stage and high UICC stage in esophageal adenocarcinomas (EACs) (tumor stage: p = 0.0209 and p < 0.0001; UICC stage: p = 0.0201 and p < 0.0001) and squamous cell carcinomas (ESCCs) (tumor stage: p = 0.0003 and p = 0.0016; UICC stage: p = 0.0026 and p = 0.0326). Additionally, overexpression of FOXO1 and loss of pSerine256-FOXO1 expression predicted shortened survival of patients with EACs (p = 0.0003 and p = 0.0133) but were unrelated to outcome in patients with ESCCs (p = 0.7785 and p = 0.8426). In summary, our study shows that overexpression of nuclear FOXO1 and loss of cytoplasmic pSerine256-FOXO1 expression are associated with poor prognosis in patients with EACs. Thus, evaluation of FOXO1 and pSerine256-FOXO1 protein expression - either alone or in combination with other markers - might be useful for prediction of clinical outcome in patients with EAC.

AB - The function of Forkhead box O 1 (FOXO1) and pSerine256-FOXO1 immunostaining in esophageal cancer is unclear. To clarify the prognostic role of nuclear FOXO1 and cytoplasmic pSerine256-FOXO1 immunostaining, a tissue microarray containing more than 600 esophageal cancers was analyzed. In non-neoplastic esophageal mucosae, FOXO1 expression was detectable in low and pSerine256-FOXO1 expression in high intensities. Increased FOXO1 and decreased pSerine256-FOXO1 expression were linked to advanced tumor stage and high UICC stage in esophageal adenocarcinomas (EACs) (tumor stage: p = 0.0209 and p < 0.0001; UICC stage: p = 0.0201 and p < 0.0001) and squamous cell carcinomas (ESCCs) (tumor stage: p = 0.0003 and p = 0.0016; UICC stage: p = 0.0026 and p = 0.0326). Additionally, overexpression of FOXO1 and loss of pSerine256-FOXO1 expression predicted shortened survival of patients with EACs (p = 0.0003 and p = 0.0133) but were unrelated to outcome in patients with ESCCs (p = 0.7785 and p = 0.8426). In summary, our study shows that overexpression of nuclear FOXO1 and loss of cytoplasmic pSerine256-FOXO1 expression are associated with poor prognosis in patients with EACs. Thus, evaluation of FOXO1 and pSerine256-FOXO1 protein expression - either alone or in combination with other markers - might be useful for prediction of clinical outcome in patients with EAC.

KW - Journal Article

U2 - 10.1038/s41598-018-35459-4

DO - 10.1038/s41598-018-35459-4

M3 - SCORING: Journal article

C2 - 30478420

VL - 8

SP - 17370

JO - SCI REP-UK

JF - SCI REP-UK

SN - 2045-2322

IS - 1

ER -